2024 Revenue Forecast for Maximus, Inc. issued by Zacks Research (NYSE:MMS)

Maximus, Inc. (NYSE:MMS – Free Report) – Equities research analysts at Zacks Research upped their FY2024 earnings estimates for shares of Maximus in a report issued on Wednesday, August 28th. Zacks Research analyst R. Department now anticipates that the healthcare provider will post earnings of $6.07 per share for the year, up from their prior estimate of $5.68. The consensus estimate for Maximus’ current full-year earnings is $5.79 per share. Zacks Research also issued estimates for Maximus’ Q4 2024 earnings at $1.42, Q2 2025 earnings at $1.39, Q3 2025 earnings at $1.47, Q4 2025 earnings at $1.51, and FY2025 earnings estimates. for $2.7 for $2.7 EPS and Q3 2026 Earnings at $1.42 EPS.

Maximum stock performance

Shares of Maximus stock opened at $92.40 on Friday. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of 24.25 and a beta of 0.75. The company’s 50-day moving average is $89.00, and its 200-day moving average is $85.53. Maximus has a 1 year low of $72.39 and a 1 year high of $93.97. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.53, and a quick ratio of 1.53.

Maximus (NYSE:MMS – Get Your Free Report ) last announced its earnings results on Wednesday, August 7th. The healthcare provider reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.27. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. Maximus had a net margin of 4.58% and a return on equity of 18.02%. The company’s quarterly revenue was up 10.6% year over year. In the same quarter last year, the business posted EPS of $0.78.

Maximus announces dividend

The company also recently announced a quarterly dividend, which will be paid on Saturday, August 31st. Stockholders of record on Thursday, August 15th will be given a dividend of $0.30 per share. This represents an annualized dividend of $1.20 and a yield of 1.30%. The ex-dividend date of this dividend is Thursday, August 15. The Maximus dividend yield is currently 31.50%.

Hedge funds weigh on Maximus

Several hedge funds and other institutional investors have recently bought and sold shares of MMS. New York State Common Retirement Fund lifted its stake in Maximus by 31.5% during the 4th quarter. New York State Common Retirement Fund now owns 31,898 shares of the health services provider’s stock, valued at $2,675,000 after acquiring an additional 7,641 shares during the period. Retirement Systems of Alabama lifted its stake in Maximus by 0.3% during the 4th quarter. Retirement Systems of Alabama now owns 76,128 shares of the health services provider’s stock valued at $6,384,000 after acquired an additional 232 shares during the period. Los Angeles Capital Management LLC boosted its stake in Maximus by 24.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 6,425 shares of the health services provider’s stock valued at $539,000 after purchasing another 1,250 shares during that period. Charles Schwab Investment Management Inc. raised its stake in Maximus by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 716,501 shares of the health services provider’s stock valued at $60,086,000 after acquiring an additional 8,702 shares during the period. Finally, Wealthspire Advisors LLC bought a new position in Maximus in the 4th quarter valued at about $1,506,000. Institutional investors own 97.21% of the company’s shares.

Maximus Company Profile

(Get a free report)

Maximus, Inc operates as a government service provider in the United States and internationally. It operates through three segments: US Federal Services, US Services, and Non-US The US Services segment provides support for program eligibility and enrollment; multilingual centralized customer contact centers, multi-channel and digital self-service options for enrollment; application assistance and independent health plan selection advice; beneficiary outreach, education, eligibility, enrollment and redeterminations; and independent person-centered disability, long-term illness, and other health assessments.

Read more

Get news and reviews for Maximus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maximus and related companies with MarketBeat.com’s FREE daily email newsletter.